Abstract:Objective: To investigate the relationship between early-stage renal acute rejection(AR) and the level of Fractalkine in urine, explore the diagnostic and noninvasive monitoring value in early stage after transplantation by measurement of urine Fractalkine. Methods: Urine samples were examined from renal transplant patients between January 2006 and October 2009. A total of 155 patients were enrolled, including 49 with biopsy-proved AR, 58 patients with stable renal function and no abnormal histological findings, 10 patients with subclinical rejection in protocol biopsy, 9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urine samples were also collected from 40 healthy controls. Fractalkine was measured in urine samples using a commercial human Fractalkine enzyme-linked immunosorbent assay (ELISA) kit. Immunohistochemistry for Fractalkine expression was performed on biopsies from renal transplant patients with AR and non-AR. Results: Forty-nine patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with stable renal function and healthy controls[(429.1±56.1)vs (94.6±8.4), (84.5±8.9)ng/mmol creatine, both P<0.001]. Patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with acute tubular necrosis and chronic allograft nephropathy[(429.1±56.1)vs(133.0±9.8), (183.0±18.9)ng/mmol creatine, both P<0.001]. Receiver operating characteristic(ROC)curve was constructed to determine the discriminatory power of Fractalkine levels for diagnosis of AR. The area under ROC curve was 0.920(95% CI: 0.875-0.969, P<0.001), which showed that Fractalkine was a suitable marker for the diagnosis of AR. At a cut-off point of 157.5 ng/mmol creatinine, the sensitivity was 83.7% and the specificity was 84.5% (P<0.001). The dynamic level of urinary Fractalkine in AR patients within 3 weeks after transplantation fluctuated above 300 ng/mmol creatine, which is remarkably higher than patients with stable renal function (below 200 ng/mmol creatinine). Conclusions: As a noninvasive monitoring method, Fractalkine in urine may be a new approach for detection of AR as well as useful to predict response to antirejection therapy. It has good sensitivity and specificity. Besides, measurement of Fractalkine in urine is a simple, inexpensive method for the routine clinical monitoring after kidney transplantation.

Perforin expression in peripheral blood lymphocyte in renal transplantation

Perforin and Granzyme B Expression in Liver Allograft Rejection

Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients

Clinical research of peripheral blood lymphocytes stimulated in vitro for immune monitoring in renal transplant recipients

Pre-transplant Impact Factors of Acute Rejection after Kidney Transplantation

[Sensitivity and specificity of granzyme B and perforin in diagnosing acute rejection after liver transplantation].

IMPACT OF PRE-TRANSPLANT SERUM LEVELS OF IP-10,MIG AND BLC ON ACUTE REJECTION EPISODE

Induction Therapies Determine the Distribution of Perforin and Granzyme B Transcripts in Kidney Transplant Recipients

ROLE OF PERIPHERAL LYMPHOCYTES SIALYL LEWIS（X）（CD15s） ANTIGEN BEFORE AND AFTER KIDNEY TRANSPLANTATION

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Acute rejection episodic outcomes resulted from pre-transplant serum level of the soluble CD30 in kidney transplant recipients

Identification of PDCD1 As a Potential Biomarker in Acute Rejection after Kidney Transplantation Via Comprehensive Bioinformatic Analysis

Treatment of rejection and highly sensitized in kidney transplantation with double filtration plasmapheresis

Relationship between cyclophilin A Mrna expression and acute rejection of human graft kidney

Clinical Implication of Monitoring Interleukin-18 Receptor on Peripheral Lymphocytes for Diagnosis and Treatment of Rejection after Renal Transplantation

Transfusion of Leukocyte-Depleted Blood in Renal Transplantation

Analysis of Granzyme B Mrna and Perforin Mrna Levels in Urine for Renal Transplantation Patients with De-Layed Graft Function

[Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients with Acute Rejection by Measurement of Urine Fractalkine].

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Donor-derived cell-free DNA can discriminate acute rejection types after kidney transplantation

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome